Medytox Korea
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Long-term Extension Study to Evaluate MBA-P01 in Subjects With Moderate to Severe Glabellar Lines (NCT05321979) | Medytox Korea | 2022-02-07 |
| A Phase II Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Moderate to Severe Glabellar Lines (NCT05217355) | Medytox Korea | 2021-12-28 |
| Study to Evaluate the Efficacy and Safety of MBA-P01 in Subjects With Glabellar Lines (NCT05059587) | Medytox Korea | 2021-08-30 |
Track Medytox Korea automatically
Every clearance here is in the API, with alerts when new ones post.